HilleVax Q3 2024 Earnings Report
Key Takeaways
HilleVax reported a net loss of $25.8 million for the third quarter of 2024, with cash, cash equivalents, and marketable securities totaling $189.3 million as of September 30, 2024. The company is exploring further development of norovirus vaccine candidates and strategic alternatives.
Cash, cash equivalents, and marketable securities totaled $189.3 million as of September 30, 2024.
Research and development expenses for the third quarter 2024 were $20.2 million, compared to $27.3 million for the third quarter 2023.
General and administrative expenses for the third quarter 2024 were $6.2 million, compared to $6.6 million for the third quarter 2023.
Net loss for the third quarter 2024 was $25.8 million, compared to $31.8 million for the third quarter 2023.